We previously reported that endogenous prostaglandins (PGs) may increase cAMP facilitated angiogenesis through the induction of vascular endothelial growth factor (VEGF) in rat sponge implantation models. In the present experiment, we tested whether or not adenylate cyclase / protein kinase A (AC/ PKA)dependent VEGF induction enhanced angiogenesis in this model. Topical daily injections of 8-bromo-cAMP enhanced angiogenesis in a dose-dependent manner. Forskolin, an activator of AC, also facilitated angiogenesis as did amrinone, an inhibitor of phosphodiesterase. VEGF induction was confirmed by the increased levels in the fluids in the sponge matrix after topical injection of 8-bromo-cAMP. Immunohistochemical investigation further revealed the VEGF-expressed cells in the sponge granulation tissues to be fibroblasts, and the intensity of positive reactions was enhanced by 8-bromo-cAMP, forskolin and amrinone. Angiogenesis without topical injections of the above compounds was suppressed by SQ22,536, an inhibitor for AC, or H-89, an inhibitor for PKA, with concomitant reductions in VEGF levels. Daily topical injections of neutralizing antibody or anti-sense oligonucleotide against VEGF significantly suppressed angiogenesis. PGE 2-induced angiogenesis was suppressed with SQ22,536 or H-89. These results suggested that AC / PKAdependent induction of VEGF certainly enhanced angiogenesis and that pharmacological tools for controlling this signaling pathway may be able to facilitate the management of conditions involving angiogenesis.
Angiogenesis is a process involved in several physiological events including embryonic development, female reproductive cycle placentation and wound repair. It also plays a part in various pathological conditions such as tumor growth, diabetic retinopathy and rheumatoid arthritis (1 -5) . Angiogenesis is a very complex multistep process involving a variety of biologically active substances. Of them, the prostaglandins (PGs), which can induce several growth factors and the proliferation of endothelial cells in vitro and in vivo (6, 7) , may be crucial for enhancing neovascularization. PGs are formed from cell membrane phospholipids through the action of several enzymes. We recently reported that PGE2 and PGI2 generated by the action of an inducible cyclooxygenase (COX), COX-2, enhanced angiogenesis via induction of a potent proangiogenic factor, vascular endothelial growth factor (VEGF) (8) . However, the precise signaling mechanisms of the endogenous PGs to facilitate angiogenesis have not been fully investigated, especially in vivo. PGE2 acts on the EP receptors and PGI2 acts on the IP receptors. Some of the EP receptor subtypes and the IP receptor are known to activate adenylate cyclase (AC) to increase the intracellular levels of cyclic AMP (cAMP). Thus, it is plausible that one of the major signaling pathways for facilitating angiogenesis may be a cAMP-dependent one.
In the present report, by using the quantitative in vivo angiogenesis model, we tested whether or not treatments that can activate adenylate cyclase / protein kinase A (AC/ PKA) pathway were responsible for increasing VEGF expression and also whether or not the elevated VEGF in fact has a role in facilitating angiogenesis.
MATERIALS AND METHODS

Rat sponge implantation model
Circular sponge discs (5-mm-thick, 1.3 cm in diameter and weighing 14.1 ± 0.1 mg, n = 6) were prepared from a sheet of polyether polyurethane foam by use of a wad pouch. The discs were soaked in 70% ethanol for 3 h and then rinsed in sterile distilled water. After drying at reduced pressure, all discs were exposed to ethylene oxide gas. They were then implanted into the subcutaneous tissue of the backs of male Sprague-Dawley (SD) strain rats (specific pathogen free, 8-week-old) that had been purchased from SLC (Hamamatsu) and were under light ether anesthesia. The day of implantation was defined as day 0. All rats were kept at constant temperature (25 ± 1°C) and humidity (60 ± 5%) with free access to normal chow and water throughout the experimental periods. The study was performed in accordance with the guidelines for animal experiments of Kitasato University School of Medicine.
Neovascularization was assessed by measuring the concentration of hemoglobin in the granulation tissues together with the enclosed sponge implants (8) . Briefly, the granulation tissues with the sponge were removed immediately after death, which was induced by the intraperitoneal administration of excess doses of sodium pentobarbital. After the granulation tissue and sponge were weighed, they were cut into several pieces with scissors. Distilled water 4 times the weight of the sample granulation tissues was added to each sample, which was then homogenized with a Polytrone homogenizer (Kinematica GmbH, Luzern, Switzerland). The hemoglobin concentration in the supernatant after centrifugation at 5,000´g was determined using a hemoglobin assay kit (Hemoglobin B Testwako; Wako Pure Chemical Industries Ltd., Osaka). The concentrations of hemoglobin in the granulation tissues were expressed as mg/g wet tissue. We previously confirmed that the hemoglobin concentrations thus determined were well correlated with the density of newly-formed blood vessels in the granulation tissues (9) , when assessed by immunohistochemical staining with von Willbrand factor (vWf) antibody (DAKO Corp., Carpinteria, CA, USA).
To assess the effects of the compounds that affect the AC / PKA-dependent signaling pathway, a number of substances were topically administered as specified below from the day of implantation (day 0) throughout the experimental periods. 8-Bromo-cAMP (Calbiochem, Darmstadt, Germany) was dissolved in physiological saline, and the solutions were daily injected (once a day, 0.05 ml/ sponge) directly into the sponge implants using a 26G needle under light ether anesthesia, at doses of 0.2, 2, and 20 nmole /site. Forskolin (Sigma, St. Louis, MO, USA), an activator of AC, and amrinone (Sigma), an inhibitor of phosphodiesterase, were dissolved in physiological saline containing 1% (V/V) DMSO; forskolin was topically injected to the sponges at doses of 100 or 300 nmol /site and amrinone, at a dose of 100 nmol /site. SQ22,536 (9-(tetrahydro-2furanyl)-9H-purin-6-amine) (Research Biochemicals International, Natick, MA, USA) and H-89 (N-(2-[p-bromocinnamylamino]ethyl)-5-isoquinolinesulfonamide) (Sigma), which are inhibitors for AC and PKA, respectively, were dissolved in physiological saline containing 1% (V /V) DMSO and topically administered throughout the experimental period, at a dose of 5, 20 or 50 nmol /site. PGE2 (Cayman Chemical, Ann Arbor, MI, USA), which are known to activate AC to increase the intracellular levels of cAMP were dissolved in ethanol and subsequently diluted 100-fold with physiological saline, and 50 m l of the latter solutions containing 30 nmol of PGE2 were injected directly into the sponge. For control rats, each vehicle solution (physiological saline or physiological saline containing 1% (V/V) DMSO) was administered topically.
Determination of cAMP levels in sponge granulation tissues
The granulation tissues were frozen immediately with acetone-dry ice. A 1-ml aliquot of phosphate buffer containing 10% trichloracetic acid (TCA) per gram of tissue were added to the sponge granulation tissues, and after the tissue was homogenized with a Polytron type homogenizer, the homogenate was centrifugated at 1500´g for 10 min at 4°C. The supernatant was transfered into a clean tube and 5 vol of ether was added to each sample to remove the TCA. After washing with ether 3 times, the resulting fluid was stocked for cAMP determination.
The levels of cAMP in sponge granulation tissues were determined with the specific ELISA for cAMP (Cayman Chemical), following protocols in the kits.
Immunohistochemical studies
The granulation tissues were immediately fixed with 4% paraformaldehyde in 0.1 M phosphate buffer solution (pH 7.4). After fixation, the tissues were dehydrated with a graded series of ethanol solutions and then embedded in paraffin. The sections (4 mm) from the paraffin-embedded tissues were mounted on glass slides, deparaffinized with xylene, and then placed in cold (4°C) acetone for immunostaining.
The procedure for staining dehydrated sections using a Vectastain ABC Kit (Vector Lab., Burlingame, CA, USA) was as follows: 1) incubation with diluted normal horse serum; 2) incubation with diluted (´500) rabbit anti-rat VEGF anti-serum (Santa Cruz Biotechnology, Santa Cruz, CA, USA); 3) incubation with biotinylated anti-rabbit IgG (7 mg/ ml); 4) incubation with avidin-biotin-peroxidase complex; 5) placement in 0.02% 3,3'-diaminobenzidine (DAB) and 0.3% nickel ammonium sulfate in 50 mM Tris-HCl buffer (pH 7.4); 6) color development by immersion in the DAB solution containing 0.005% H2O2; and 7) examination and photomicrography with a light microscope. To avoid non-specific staining of VEGF, we used the ´500 diluted antibody in the present experiment.
Determination of VEGF levels in fluids in sponge matrix
Under light ether anesthesia, the fluids in the sponge matrix were collected by aspiration with a 26G needle, and then they were centrifuged at 2,000´g for 20 min. The resulting supernatant was diluted with the assay buffer in ELISA for VEGF, and the levels were determined with the specific ELISA for mouse VEGF (Genzyme, Cambridge, MA, USA). The antibody against mouse VEGF in this kit showed nearly 100% cross-reactivity with rat VEGF, and the levels of VEGF were expressed in terms of mouse VEGF, since the standard curve was drawn using the authentic mouse VEGF in the kit.
Administration of neutralizing antibody and anti-sense oligonucleotide against VEGF
To the rats receiving sponge implants, anti-mouse VEGF IgG (Genzyme, 200 mg/ ml in PBS) was administrated topically for 6 days (10 mg/ site, 50 m l /site, once a day), and angiogenesis was estimated by determination of the Hb concentration in the sponge granuloma. For control rats, a non-immune IgG fraction (Genzyme, 10 mg/site, once a day) was administered topically. To some rats receiving topical injections of anti-mouse IgG, SQ22,536 (50 nmol / site) and H-89 (20 nmol / site) was administered topically for 6 days.
Anti-sense oligonucleotide against VEGF, which consists of 20 nucleotide residues (agagcagaaagttcatggtt) of the 5'-terminal of VEGF gene, were administered at 25 nmol / site, topically twice a day for 6 days. For control rats, a randomized control oligonucleotide (gtactgatagaatgagtagc), which has the same nucleic acid components but a randomized composition, was administered topically.
Statistical analyses
All values were expressed as the means ± S.E.M. The statistical difference between the two groups was examined using Student's unpaired t-test after confirming that the variance of data was not heterogeneous. For the results from multiple groups, factorial ANOVA was used to evaluate the significance of differences, followed by Scheffe's test. A P value of less than 0.05 was considered to be significant.
RESULTS
When circular sponge discs were implanted into rat subcutaneous tissues, granuloma tissues constituted mainly of collagen fibers developed around the implants. In this model, angiogenesis was quantified by the determination of hemoglobin concentrations in the granulation tissues. Direct topical injections of 8-bromo-cAMP for 6 days significantly facilitated angiogenesis in a dose-dependent manner ( Fig. 1 ), suggesting that the cAMP-dependent pathway significantly facilitates angiogenesis in this model.
Topical injections of forskolin and amrinone increased cAMP levels in the granulation tissues ( Fig. 2a ). As shown in Fig. 2b , angiogenesis, as assessed from Hb concentrations, was significantly increased by topical injections of forskolin in a dose-dependent manner, and it was also increased by topical injections of amrinone. These findings suggested that the activation of AC or the accumulation of cAMP in the sponge granulation tissues increase the angiogenesis in this model.
To assess the roles of the AC /PKA signaling pathway, we administered an inhibitor of AC in this model. The naturally occurring angiogenesis was significantly reduced by daily topical injections of SQ22,536 in a dose-dependent manner (Fig. 3) . Furthermore, the topical administration of H-89, an inhibitor for PKA, also reduced the intensity of this naturally occurring angiogenesis. The activation of the AC /PKA signaling pathway may have the function of enhancing naturally occurring angiogenesis in this model. This hypothesis was further supported by the result observed in angiogenesis enhanced by topical injection of forskolin or amrinone. H-89 and SQ22,536 inhibited the angiogenesis stimulated with forskolin or amrinone ( Fig. 4 : a and b). This effect of H-89 and SQ22,536 was also seen in the angiogenesis enhanced by PGE2 ( Fig. 4c ), suggesting that PGE2 also enhanced angiogenesis through this signaling pathway.
The VEGF levels in the fluids collected from the sponge matrix were significantly raised by topical injections of 8-bromo-cAMP, but significantly reduced by the topical injections of SQ22,536 or H-89 ( Fig. 5) .
Immunohistochemical studies revealed that the VEGFpositive cells in non-stimulated sponge granulation tissues were mainly fibroblast-like cells surrounding neovascularized endothelial cells (Fig. 6 ). The positive reaction to VEGF was obvious in the 8-bromo-cAMP-stimulated sponge granulomas, together with a concomitant increase in density of neovascularization ( Fig. 6b ), compared with vehicle-treated sponges (Fig. 4a ). Forskolin or amrinone also increased both positive reactions of VEGF and angiogenesis ( Fig. 6: c and d) . In contrast, SQ22,536 and H-89 markedly reduced density of neovascularization and VEGF-positive stains.
The contribution of expressed VEGF to the enhancement of angiogenesis in this model was finally examined by means of topical injections of neutralizing antibody and anti-sense oligonucleotide against VEGF. Topical daily injections of VEGF-antibody markedly reduced angiogenesis in the sponge granulation tissues stimulated with 8-bromo-cAMP. This inhibitory effect was further enhanced with concomitant topical administrations of H-89 or SQ22,536 ( Fig. 7) . Topical daily injections of VEGF anti-sense oligonucleotide into the sponge for 6 days resulted in a significant (P<0.05) reduction in angiogenesis (day 5, 1.8 ± 0.3 mg/ g wet tissue, n = 6) in comparison with the angiogenesis seen under treatment with randomized control oligonucleotide (day 5, 5.3 ± 0.5 mg /g wet tissue, n = 6). 
DISCUSSION
The angiogenesis assay used in the present study was designed to quantify angiogenesis in vivo. The degree of angiogenesis in granuloma tissues can be estimated from the amount of dye injected intravenously (10) . We, however, instead determined the hemoglobin content of the sponge granuloma tissues, considering hemoglobin a good marker for angiogenesis in this model (8 -11) . When temporal and spatial neovascularization in the sponge granuloma tissues was also confirmed by a histologic and immunohistochemical study using antibody raised against vWF, which is a marker of endothelial cells, a good positive correlation between the Hb concentration and the density of newly-formed vessels was observed (9) . We previously reported that neovascularization with topical administrations of bFGF, EGF, PGE2 and PGI2 was enhanced in a dose-dependent manner with good reproducibility, suggesting that the method used in the present experiment was reliable for quantifying angiogenesis (8, 9) . The advantages of this model are that the endogenous substances formed during angiogenesis can be easily collected from the implant and can be measured and that the capacity for exogenous substances to affect angiogenesis can be investigated by the direct injection of these substances into the sponges. Sponge granulation tissue gradually increased over a 14-day period (12) . We estimated the effect of angiogenesis in this model at day 6 by the reason of having half value of 14 days. At this stage, we can estimate pro-angiogenic or anti-angiogenic responses with enough reproducibility. Making use of this model, we estimated the contribution of cAMP-dependent signaling to angiogensis.
Angiogenesis is a very complex multistep process involving a variety of biologically active substances. Of these, PGs, which can induce several growth factors and the proliferation of endothelial cells in vitro and in vivo (6, 7) , may be crucial for enhancing neovascularization. PGs are formed from cell membrane phospholipids through the action of several enzymes. We recently reported that topical injections of PGE2 or PGI2 in the same model as that used in the present study increased the mRNA levels of VEGF, a potent proangiogenic factor in the granulation tissues, and that endogenous PGE2 or PGI2 (or both), generated through the action of an inducible COX-2, enhanced angiogenesis via induction of VEGF. COX-2 selective inhibitors were known to suppress the tumor growth at least partly through the inhibition of angiogenesis in response to COX-2 inhibition (13) . In our previous reports, COX-2 selective inhibitors such as NS-398, JTE-522, and nimesulide inhibited angiogenesis (8, 12) . However, the precise signaling mechanisms of the endogenous PGs to facilitate angiogenesis have not been fully investigated, especially in vivo. The PGI 2 receptor, namely the IP receptor, is a G protein-coupled rhodopsin type receptor, and its signal transduction pathway is an AC/ PKA-dependent one (14) . PGE2 acts on EP receptors, which have 4 subtypes, EP1, EP2, EP3 and EP4. Some of the EP receptor subtypes, such as EP2 and EP4, and the IP receptor are known to activate AC to increase the intracellular levels of cAMP. Thus, it is plausible that one of the major signaling pathways to facilitate angiogenesis may be the AC/PKAdependent one. In the present report, we used a quantitative in vivo angiogenesis model, and we tested whether or not the AC / PKA-dependent signaling pathway was responsible for inducing VEGF expression that may actually potentiate angiogenesis in vivo.
It has frequently been reported that cAMP-dependent signaling was responsible for the induction of VEGF in many cultured cells. In human endometrial stromal cells that can induce unique cycle-specific angiogenesis, cAMP, a known stimulus for endometrial decidualization, can induce VEGF in vitro (15) . Cells from the endocrine systems, which have a rich vasculature, such as those from the adrenal gland, also secreted VEGF in response to cAMP 16) . In retinal pericytes, VEGF expression was increased by the activation of the cAMP-dependent PKA pathway (17) . Adipocytes also increased the expression of VEGF by AC/ PKA activation (18, 19) . It is widely accepted that tumor growth was dependent on the intensity of angiogenesis (2) , and the immunohistochemical detection of VEGF in tumor cells has been reported repeatedly. Lung cancer cells showed increased expression of VEGF in response to PGE 2 and forskolin, which was inhibited by H-89, a PKA inhibitor, suggesting that cAMP activates PKA (20) . In rat cultured Muller cells, the increased expression of the mRNA of VEGF seemed to occur through the activation of the PKA pathway also (21) . The present immunohistochemical studies revealed the VEGF-positive cells in the sponge granulation tissues to be mainly fibroblasts ( Fig. 6 ). cAMP-dependent increase in VEGF expression was also reported in fibroblasts isolated from the rat aorta (22) . In the synovial fibroblasts from the patients with rheumatoid arthritis, the AC / PKA pathway mediated the effect of PGE2 in increasing the expression of VEGF (23) . In that paper, Rp-cAMP, a cAMP antagonist, suppressed VEGF expression induced by PGE2 (23) . cAMPdependent increase in VEGF expression was also observed in isolated organs such as perfused rat lungs and human fetal lung explants (24, 25) .
However, there has been no clarification as to whether the AC /PKA signaling pathway actually enhanced angiogenesis in vivo through the action of VEGF. In the present study, we demonstrated that this signaling pathway certainly contributed to angiogenesis via VEGF. A cAMP analogue, 8-bromo-cAMP, when applied topically, enhanced both the expression of VEGF and angiogenesis, suggesting that the activation of AC may be relevant to the development of angiogenesis through the induction of VEGF. In fact, forskolin, an activator of AC, which increases cAMP, certainly facilitates angiogenesis together with increased expression of VEGF. This was also true in the case of the inhibition of cAMP degrading enzyme, phosphodiesterase, by amrinone. This enhancement of angiogenesis and VEGF expression by forskolin or amrinone certainly has the concomitant increase in cAMP levels in the granulation tissues. SQ22,536, an inhibitor of AC, reduced angiogenesis together with the reduction in VEGF levels in the sponge matrix. The cAMP generated through the action of AC was responsible for the activation of PKA, judging from the inhibitory effect on angiogenesis of H-89 administered topically. The effect of angiogenesis by topical injections of forskolin or amrinone reduced by those of SQ22,536 or H-89. PGE 2-induced angiogenesis was also inhibited by in SQ22,536 or H-89 ( Fig. 4) . These results taken together suggested that that the cAMP generated through the action of AC increased the expression of VEGF via the PKA-dependent pathway in parallel with facilitation of angiogenesis in this in vivo angiogenesis model. Furthermore, it is highly plausible that PGE2 utilized the same signaling pathway to enhance angiogenesis in this model. Immunohistochemical study revealed that VEGF was expressed in the fibroblasts, not in the endothelial cells, in the sponge granulation tissues. This suggested that a full set of the components of the AC /PKA signaling pathway may be contained in the fibroblasts. Compared with vehicle, the predominant reactions were seen in the 8-bromo-cAMP, forskolin, and amrinone sample (Fig. 6) . The present study is the first to report that an AC/ PKAdependent increase in the VEGF in fibroblasts may be relevant to angiogenesis in vivo, acting on the endothelial cells in a paracrine fashion, although it was previously reported that the fibroblasts generated VEGF via the AC / PKA-dependent pathway in vitro (22, 23) . The expressed VEGF certainly has a role in the facilitation of angiogenesis, since the topical injections of neutralizing antibody or antisense oligonucleotide against VEGF significantly suppressed angiogenesis in this model. This inhibitory effect of VEGF antibody was further enhanced by the concomitant topical injections of H-89 or SQ22,536 ( Fig. 7) . Although the possible involvement of other growth factors such as bFGF, PDGF or TGFb, which may induce the AC / PKA signaling pathway, cannot be ruled out in this angio- genesis model, it is plausible that VEGF is a predominant factor to enhance angiogenesis via the PC / PKA-dependent pathway.
We conclude from our above results that, in this in vivo angiogenesis model with chronic and proliferative characteristics of inflammation, the AC /PKA-dependent increase in VEGF certainly enhanced angiogenesis and that the pharmacological tools for controlling this signaling pathway may be able to facilitate the management of conditions involving angiogenesis.
